Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients
Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Patients.
First clinical patient dosed at Cross Cancer Institute, Edmonton.
